Phase 3Active, not recruiting

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)

A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity

Sponsor
Eli Lilly and Company (Industry)
Enrollment
15,374 enrolled
Conditions
Obesity; Overweight
Interventions
Tirzepatide; Placebo
Ages
adults, older adults
Registry
NCT05556512, CTIS2022-501744-15-00

Full record on ClinicalTrials.gov

From the registry

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.

Primary outcomes

  • Time to First Occurrence of Any Component Event of Composite (All-Cause Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Coronary Revascularization, or Heart Failure Events)

History

  1. Primary completion expected

  2. Last registry update

  3. Started

  4. Registered

Papers citing this trial

In the news